Skip to content

PTSD early intervention and prevention

TL;DR — Universal single-session psychological debriefing does not prevent PTSD and may worsen outcomes; across 11 trials, short-term PTSD OR was 1.22 (95% CI .60–2.46), and one trial’s one-year OR was 2.88 (1.11–7.53) (Rose 2002, PMID 12076399). This must not be conflated with targeted early trauma-focused CBT for people with acute stress disorder or substantial early symptoms, which has supportive evidence (Bryant 2007, PMID 21352105). Most trauma survivors recover without formal intervention, so prevention must balance benefit, burden and overtreatment. Pharmacologic prevention remains investigational.

Universal versus indicated

Universal interventions treat everyone exposed; selective approaches target higher-risk groups; indicated approaches target early symptoms. Pooling them obscures benefit and overtreatment.

Debriefing

Compulsory emotional-processing debriefing should cease according to the Cochrane review (Rose 2002, PMID 12076399). Psychological first aid, practical support and stepped monitoring are different interventions.

Early trauma-focused CBT

Evidence is strongest when early treatment is offered to symptomatic/high-risk people rather than universally (Bryant 2007, PMID 21352105). Timing, dose and spontaneous recovery complicate absolute effects.

Pharmacologic prevention

Hydrocortisone and propranolol have biologic rationales, developed from glucocorticoid and noradrenergic accounts of traumatic memory consolidation (Florido 2023, PMID 36402246) (Giustino 2016, PMID 26808441). The clinical evidence is thinner than the rationale. A systematic review and meta-analysis of 19 RCTs of pharmacotherapy started within three months of a traumatic event (16 adult, 3 pediatric) found only hydrocortisone superior to placebo in adults for preventing PTSD (3 studies, n=88; RR 0.21, 95% CI 0.05–0.89), and that signal came from populations with severe physical illness, which bounds its generalisability; propranolol, oxytocin, gabapentin and the other agents tested showed no significant effect, and most trials were of low methodological quality (Astill Wright 2019, PMID 31819037). Memory-modification ethics and medical contraindications require explicit handling.

Screening

High sensitivity can over-treat many who would recover; high specificity misses people whose symptoms emerge later. Prediction models need calibration and decision-curve evaluation.

Mass trauma

Scalable monitoring, material support, safety and access may matter more than one protocol. Disaster, ICU, childbirth and assault studies should not be pooled without trauma-context analysis (Dekel 2024, PMID 38122842).

Outcome

Prevention trials should measure PTSD incidence, symptom burden, function, adverse effects and health-service use, not only short-term symptom scores.

Quantitative anchors

Measure Estimate Population/method Source
Debriefing 11 trials No prevention; possible harm (Rose 2002, PMID 12076399)
Short-term PTSD after debriefing OR 1.22 (95% CI .60–2.46) 3–5 months (Rose 2002, PMID 12076399)
One-year PTSD in one trial OR 2.88 (95% CI 1.11–7.53) Debriefing vs control (Rose 2002, PMID 12076399)
Targeted early CBT supportive RCT evidence Acute stress disorder/high symptoms (Bryant 2007, PMID 21352105)
Early pharmacotherapy evidence base 19 RCTs (16 adult, 3 pediatric); most low quality Within 3 months of trauma (Astill Wright 2019, PMID 31819037)
Hydrocortisone for PTSD prevention RR 0.21 (95% CI 0.05–0.89) 3 studies; n=88; severe physical illness (Astill Wright 2019, PMID 31819037)
Propranolol, oxytocin, gabapentin and others no significant preventive effect Same review (Astill Wright 2019, PMID 31819037)

Evidence ledger

The ledger lists the live-retrieved records used to bound this page. Inclusion does not make every record equally probative; design, population and comparator remain decisive.

PMID Year Evidence contribution Scope caution
12076399 2002 Psychological debriefing for preventing post traumatic stress disorder (PTSD). PTSD-specific record; inspect design and population
21352105 2007 Early intervention for post-traumatic stress disorder. PTSD-specific record; inspect design and population
38122842 2024 Preventing posttraumatic stress disorder following childbirth: a systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
36077489 2022 Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder. PTSD-specific record; inspect design and population
29712466 2018 Eradicating Traumatic Memories: Implications for PTSD Treatment. PTSD-specific record; inspect design and population
36402246 2023 Glucocorticoid-based pharmacotherapies preventing PTSD. PTSD-specific record; inspect design and population
30380933 2018 Reconsolidation of Traumatic Memories Using Psychotherapy. PTSD-specific record; inspect design and population
29175821 2018 Post-traumatic stress after PICU and corticosteroid use. PTSD-specific record; inspect design and population
18852564 2008 Neuroethics and psychiatry. PTSD-specific record; inspect design and population
19800725 2009 Emerging treatments for PTSD. PTSD-specific record; inspect design and population
17849332 2007 Spinoza's Passions. PTSD-specific record; inspect design and population
30290789 2018 Salivary cortisol in post-traumatic stress disorder: a systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
31918435 2020 The 24-hour urinary cortisol in post-traumatic stress disorder: A meta-analysis. Synthesis: preserve included-population and certainty limits
17338596 2007 Gender differences in posttraumatic stress disorder. PTSD-specific record; inspect design and population
26808441 2016 Revisiting propranolol and PTSD: Memory erasure or extinction enhancement? PTSD-specific record; inspect design and population
11470035 2001 Post-traumatic stress disorder: a review of recent findings. Synthesis: preserve included-population and certainty limits
10795605 2000 Biology of posttraumatic stress disorder. PTSD-specific record; inspect design and population
9670231 1998 Psychoneuroendocrinology of post-traumatic stress disorder. PTSD-specific record; inspect design and population
23301571 2013 Memory and memories. PTSD-specific record; inspect design and population
22481399 2012 Remembered for forgetting. PTSD-specific record; inspect design and population
37080870 2023 Rapid and efficient treatment of post-traumatic stress disorder induced by anaesthesia awareness with recall using reconsolidation therapy. PTSD-specific record; inspect design and population
36973385 2023 Investigating TSPO levels in occupation-related posttraumatic stress disorder. PTSD-specific record; inspect design and population
1661614 1991 Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. PTSD-specific record; inspect design and population
9329447 1997 The psychobiology of posttraumatic stress disorder. PTSD-specific record; inspect design and population
24785767 2014 Rates of post-traumatic stress disorder in trauma-exposed children and adolescents: meta-analysis. Synthesis: preserve included-population and certainty limits
27865585 2017 The prevalence of posttraumatic stress disorder in pregnancy and after birth: A systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
31819037 2019 Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Most included trials at low methodological quality; hydrocortisone signal from medically ill samples

Interpretation guardrails

  • Trauma exposure, post-traumatic symptoms, acute stress disorder, DSM-5 PTSD, ICD-11 PTSD and ICD-11 complex PTSD are not interchangeable populations.
  • A mixed-anxiety or transdiagnostic estimate is labelled as such; only a source’s PTSD stratum can be treated as a PTSD effect.
  • Comorbid depression is measured separately and cross-linked to the depression condition; it is not absorbed into PTSD.
  • Waitlist, treatment-as-usual, attention control and active treatment answer different causal questions.
  • Registration, statistical significance and diagnostic loss do not respectively prove completion, clinical importance or functional recovery.
  • This page synthesizes research and does not provide individual medical advice.

Minimum extraction frame for studies on this topic

Field What must be retained Why it changes interpretation
Diagnostic system DSM version, ICD version, full/subthreshold Case mix is not interchangeable
Diagnostic method Structured interview, clinician judgment, self-report cutoff Screening is not diagnosis
Index trauma Type, timing, repetition, direct/indirect/occupational Conditional risk and phenotype differ
Population Civilian, veteran, refugee, child/adolescent, mixed Transportability is empirical
Baseline severity Mean, SD, range and exclusion threshold Ceiling and floor effects alter change
CPTSD status ITQ/ICD-11 definition and DSO score Complexity cannot be inferred from trauma count
Comorbidity Depression, GAD, SUD, pain, TBI measured separately Shared symptoms can distort effects
Comparator Waitlist, usual care, attention, active treatment The estimand changes with comparator
Treatment dose Sessions offered/attended, duration, homework Assignment is not exposure
Outcome Symptoms, diagnosis, response, function, sleep Outcomes are not interchangeable
Time point End point and prespecified follow-up windows Acute benefit may not persist
Missing data Denominator, reasons, imputation and estimand Attrition can bias rank and magnitude
Adverse events Definitions, ascertainment and arm-level counts Absence of reporting is not absence of harm
Therapist/context Training, fidelity, allegiance, setting Delivery is part of the intervention
Funding/conflicts Sponsor role and analytic independence Especially material for proprietary packages

Claims this page does not make

  • It does not infer PTSD from trauma exposure alone.
  • It does not treat a self-report cutoff as equivalent to a structured diagnosis.
  • It does not convert a pooled anxiety-disorder effect into a PTSD effect.
  • It does not convert a depression outcome in a comorbid sample into a PTSD outcome.
  • It does not infer superiority from a statistically significant within-group change.
  • It does not infer equivalence from a non-significant between-group test.
  • It does not infer effectiveness from trial registration or mechanistic plausibility.
  • It does not assume military, civilian, refugee and pediatric estimates transport unchanged.
  • It does not average conflicting estimates that use different definitions.
  • It does not treat lack of adverse-event reporting as evidence of safety.

Evidence-updating triggers

Trigger Required response
New diagnostic revision Recalculate which populations prior estimates represent
New head-to-head RCT Compare against active treatment, not only waitlist
New individual-participant synthesis Revisit effect modifiers and transportability
Registry status change Verify results and linked publication before changing conclusions
Guideline update Separate evidence review from panel recommendation
Regulatory decision Record decision date and source; do not infer from efficacy papers
Safety signal Re-extract denominator, ascertainment and exposure time by arm
Contradictory replication Display estimates side by side; do not average definitions

Evidence updates should preserve the prior estimate and explain why the new study changes—or does not change—the inference.

Open questions

  • Can risk-stratified stepped care improve absolute outcomes without pathologising normal recovery? (Bryant 2007, PMID 21352105)
  • Which pharmacologic prevention signals survive large preregistered replication? (Florido 2023, PMID 36402246)
  • What is the optimal timing and symptom threshold for early trauma-focused CBT? (Bryant 2007, PMID 21352105)

References

  1. Rose S, et al. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2002;(2):CD000560. PMID 12076399
  2. Bryant RA Early intervention for post-traumatic stress disorder. Early Interv Psychiatry. 2007;1(1):19-26. PMID 21352105
  3. Dekel S, et al. Preventing posttraumatic stress disorder following childbirth: a systematic review and meta-analysis. Am J Obstet Gynecol. 2024;230(6):610-641.e14. PMID 38122842
  4. Szeleszczuk Ł, et al. Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder. Int J Mol Sci. 2022;23(17):10099. PMID 36077489
  5. Friedman MJ Eradicating Traumatic Memories: Implications for PTSD Treatment. Am J Psychiatry. 2018;175(5):391-392. PMID 29712466
  6. Florido A, et al. Glucocorticoid-based pharmacotherapies preventing PTSD. Neuropharmacology. 2023;224:109344. PMID 36402246
  7. Waits WM, et al. Reconsolidation of Traumatic Memories Using Psychotherapy. Am J Psychiatry. 2018;175(11):1145. PMID 30380933
  8. Corbet Burcher G, et al. Post-traumatic stress after PICU and corticosteroid use. Arch Dis Child. 2018;103(9):887-889. PMID 29175821
  9. Levy N, et al. Neuroethics and psychiatry. Curr Opin Psychiatry. 2008;21(6):568-71. PMID 18852564
  10. Cukor J, et al. Emerging treatments for PTSD. Clin Psychol Rev. 2009;29(8):715-26. PMID 19800725
  11. Trachtman H Spinoza's Passions. Am J Bioeth. 2007;7(9):21-3. PMID 17849332
  12. Pan X, et al. Salivary cortisol in post-traumatic stress disorder: a systematic review and meta-analysis. BMC Psychiatry. 2018;18(1):324. PMID 30290789
  13. Pan X, et al. The 24-hour urinary cortisol in post-traumatic stress disorder: A meta-analysis. PLoS One. 2020;15(1):e0227560. PMID 31918435
  14. Olff M, et al. Gender differences in posttraumatic stress disorder. Psychol Bull. 2007;133(2):183-204. PMID 17338596
  15. Giustino TF, et al. Revisiting propranolol and PTSD: Memory erasure or extinction enhancement? Neurobiol Learn Mem. 2016;130:26-33. PMID 26808441
  16. Seedat S, et al. Post-traumatic stress disorder: a review of recent findings. Curr Psychiatry Rep. 2001;3(4):288-94. PMID 11470035
  17. Yehuda R Biology of posttraumatic stress disorder. J Clin Psychiatry. 2000;61 Suppl 7:14-21. PMID 10795605
  18. Yehuda R Psychoneuroendocrinology of post-traumatic stress disorder. Psychiatr Clin North Am. 1998;21(2):359-79. PMID 9670231
  19. Flaskerud JH Memory and memories. Issues Ment Health Nurs. 2013;34(1):59-61. PMID 23301571
  20. Willyard C Remembered for forgetting. Nat Med. 2012;18(4):482-4. PMID 22481399
  21. Laurin A, et al. Rapid and efficient treatment of post-traumatic stress disorder induced by anaesthesia awareness with recall using reconsolidation therapy. Br J Anaesth. 2023;130(6):e483-e485. PMID 37080870
  22. Watling SE, et al. Investigating TSPO levels in occupation-related posttraumatic stress disorder. Sci Rep. 2023;13(1):4970. PMID 36973385
  23. Yehuda R, et al. Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. Biol Psychiatry. 1991;30(10):1031-48. PMID 1661614
  24. van der Kolk BA The psychobiology of posttraumatic stress disorder. J Clin Psychiatry. 1997;58 Suppl 9:16-24. PMID 9329447
  25. Alisic E, et al. Rates of post-traumatic stress disorder in trauma-exposed children and adolescents: meta-analysis. Br J Psychiatry. 2014;204:335-40. PMID 24785767
  26. Yildiz PD, et al. The prevalence of posttraumatic stress disorder in pregnancy and after birth: A systematic review and meta-analysis. J Affect Disord. 2017;208:634-645. PMID 27865585
  27. Astill Wright L, et al. Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Transl Psychiatry. 2019;9(1):334. PMID 31819037